— The Board of Directors and Management Remain Committed to Maximizing Shareholder Value by Executing the Company’s Strategic Plan —
Keep The Hunger On: Analyst Says Soleno Therapeutics’ Upside Potential Much Higher Than Downside Risk
Cantor Fitzgerald has initiated coverage on Soleno Therapeutics Inc (NASDAQ: SLNO) with an Overweight rating and a